uniQure Announces Financial Results for Second Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
August 27, 2015 12:02 PM EDTChardan Capital trims its price target on uniQure N.V. (Nasdaq: QURE) from $40 to $35 and maintains a Buy rating following Q2 results and update issued earlier.
Analyst Gbola Amusa noted that the lowered price target stems from (1) uncertainty for Glybera... More
uniQure (QURE) Reports Q2 Loss of EUR0.51/Share
August 27, 2015 6:07 AM EDTuniQure (NASDAQ: QURE) reported Q2 EPS of (EUR0.51), versus (EUR0.87) reported last year. Revenue for the quarter came in at EUR1.04 million, versus EUR1.62 million reported last year.
Pipeline Updates
Hemophilia B: Dosing is underway in the Phase I/II study of AMT-060 in hemophilia B and the Company anticipates... More


